Published: 2018-02-22

Analgesic activity of Alpinia galanga extract in mice models and TNF-alpha receptor computational docking analysis on its leads with pharmacokinetics prediction

K. R. Subash, G. Francis Britto, Katari Sudheer Kumar, Amineni Umamaheshwari, Vijaya Chandra Reddy Konda, Bhanu Prakash G.


Background: Alpinia galanga is an ayurvedic herb recognized and used across many traditional medicine systems for its analgesic and anti-inflammatory activity. The present study scientifically validates the potential anti nociceptive action of ethanolic extract of Alpinia galanga by chemical, neurogenic and inflammatory nociception model in mice followed by identification of potential lead compound by computational analysis.

Methods: The assessment of anti nociceptive action is evaluated by Acetic acid induced abdominal constrictions and Formalin assay on ethonolic extract of Alpinia galanga, followed by 20 compounds with known chemical structure of Alpinia galanga is subjected to computational analysis to predict possible lead compound with desirable pharmacokinetic and drug like features.

Results: The percentage inhibition rate of Aspirin (100mg/kg) was 82.15% compared to Alpinia galanga (100mg/kg) 19.63%, (200mg/kg) 33.02% and (400mg/kg) 57.13% by acetic acid induced abdominal constrictions antinociceptive mice model. Alpinia galanga 400mg/kg (71.70%) had comparable percentage inhibition of nociception to standard group indomethacin (88.71%) in formalin induced nociceptive mice model. Among 20 compounds screened for pharmacokinetic and drug like features, Galanal B had the binding free energy -56.664 when compared to control compound 2AZ5-56.000.

Conclusions: The Alpinia galanga extract had significant anti nociceptive activity and followed by computational analysis of 20 compounds with known chemical structure predicted Galanal B as lead compound with best insilico pharmacokinetic and drug like features.


Alpinia galanga, Formalin assay, Insilico, Nociception, QSAR

Full Text:



Arambewela LS, Arawwawala M, Owen NL, Jarvis B. Volatile oil of Alpinia galanga wild of Sri Lanka. J Essent Oil Res. 2007;19(5):455-6.

Grzanna R, Lindmark L, Frondoza CG. Ginger - An herbal medicinal product with broad anti-inflammatory actions. J Med Food. 2005;8(2):125-32.

Higgs GA, Moncada S, Vane JR. Eicosanoids in inflammation. Ann Clin Res. 1984;16(5-6):287-99.

Koster R, Anderson M, De Beer A.J. Acetic acid for analgesic screening. Fed Proc. 1959;18:412-6.

Dubuisson D, Dennis SG. The formalin test: A quantitative study of the analgesic effects of morphine, meperidine and brain stem stimulation in rats and cats; Pain. 1977;4:161-74.

Arambewela Lakshmi Sri Lankan Medicinal plant Monograph and Analysis: Alpinia galanga Lakshmi Arambewela and Aravinda Wijesinghe.- Colombo: National Science Foundation,. Sri Lankan Medicinal Plants. 2006;10:36.

Schrödinger Release 2013-3: Maestro, version 9.6, Schrödinger, LLC, New York, NY, 2013.

Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. March 2001;46(1-3):3-26.

Chopra RN, Chopra IC, Honda KL, Kapur LD. Alpinia galanga Wild. Chopra's Indigenous Drugs of India, U.N Dhur and Sons Pvt. Ltd., Calcutta. 1958:274-276.

Grzanna R, Lindmark L, Frondoza C. Ginger-A herbal medicinal product with broad anti-inflammatory actions. J. Med. Food. 2005;8(2):125-32.

Kaleysa RR, Raj RK. Screening of indigenous plants for anthelmintic action against human Ascari's lumbricoides Indian Journal of Physiology and Pharmacology. 1975;19(1):47-9.

Ogiso A, Kabayashi S. Antiulcer agents from Alpinia seeds Japan Kokai. 1974;74:36.

Puri HS. Vegetable aphrodisiac of India, Quart, J. Crude Drug Res. 1971;11(2):1742-8.

Haraguchi H, Kuwata Y, Inada K, Shingn K, Mujahara K, Nagao M, et al. Antifungal activity from Alpinia galanga on the competition for incorporation of unsaturated fatty acids in cell growth Planta Medica, 1996;62(4):308-13.

Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discovery Today: Technologies. 2004;1(4):337-41.